NEW YORK (TheStreet) -- Keryx Biopharmaceuticals
(KERX - Get Report) shares are plummeting, down -13.5% to $12.30, on Thursday after the company posted a net loss more than 10 cents per share worse than it reported last year.
The biotech company posted a net loss of $13.5 million, or -15 cents per share, missing analysts estimates by 7 cents. The company reported a net loss of -2 cents and $2.1 million during the same period last year.
Must Read: Warren Buffett's 10 Favorite Growth Stocks
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts